Spero Therapeutics Inc - ESG Rating & Company Profile powered by AI
The page includes a Q&A section for Spero Therapeutics Inc. The page is a zero-cost Sustainability analysis for Spero Therapeutics Inc. Full Sustainability analysis of Spero Therapeutics Inc are accessed by logging in.
Spero Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.8; made up of an environmental score of 2.0, social score of 3.2 and governance score of 3.2.
2.8
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1353 | Vera Therapeutics Inc | 2.9 | Medium |
| 1353 | Veracyte Inc | 2.9 | Medium |
| 1393 | Spero Therapeutics Inc | 2.8 | Medium |
| 1393 | Bioventix PLC | 2.8 | Medium |
| 1393 | Bolt Biotherapeutics Inc | 2.8 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Spero Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Spero Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Spero Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Spero Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Spero Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Spero Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Spero Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Spero Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Spero Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Spero Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Spero Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Spero Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Spero Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Spero Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Spero Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Spero Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Spero Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Spero Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Spero Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Spero Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Spero Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Spero Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Spero Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Spero Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Spero Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Spero Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Spero Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Spero Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Spero Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Spero Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Spero Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Spero Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Spero Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Spero Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Spero Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Spero Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Spero Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.